GlaxoSmithKline Inc., which is producing the Canadian order of H1N1 influenza vaccine at its plant in Ste-Foy, Que., said it asked provincial and territorial health authorities Wednesday to stop using doses from a specific lot shipment distributed late last month.
“(GlaxoSmithKline) is taking this cautionary action because (the Public Health Agency of Canada) has received a higher than expected number of reports of anaphylaxis in this lot number compared to other lots,” company spokeswoman Megan Spoore said in a statement. “On an ongoing basis (GlaxoSmithKline) is working with Health Canada to ensure that each vaccine lot released to the provinces and territories consistently meets quality and safety standards.”
The batch under investigation by the federal government and GlaxoSmithKline bears the lot number A80CA007A brand name Arepanrix, which is the version that contains adjuvant, a chemical additive that stretches supply and boosts immunity.
Full article here